Skip to main content
PMC home page
CMAJ : Canadian Medical Association Journal logoLink to CMAJ : Canadian Medical Association Journal
. 1991 Dec 15;145(12):1571–1581.

Non-insulin-dependent (type II) diabetes mellitus.

W Rodger 1
PMCID: PMC1336077  PMID: 1742694

Abstract

Non-insulin-dependent (type II) diabetes mellitus is an inherited metabolic disorder characterized by hyperglycemia with resistance to ketosis. The onset is usually after age 40 years. Patients are variably symptomatic and frequently obese, hyperlipidemic and hypertensive. Clinical, pathological and biochemical evidence suggests that the disease is caused by a combined defect of insulin secretion and insulin resistance. Goals in the treatment of hyperglycemia, dyslipidemia and hypertension should be appropriate to the patient's age, the status of diabetic complications and the safety of the regimen. Nonpharmacologic management includes meal planning to achieve a suitable weight, such that carbohydrates supply 50% to 60% of the daily energy intake, with limitation of saturated fats, cholesterol and salt when indicated, and physical activity appropriate to the patient's age and cardiovascular status. Follow-up should include regular visits with the physician, access to diabetes education, self-monitoring of the blood or urine glucose level and laboratory-based measurement of the plasma levels of glucose and glycated hemoglobin. If unacceptably high plasma glucose levels (e.g., 8 mmol/L or more before meals) persist the use of orally given hypoglycemic agents (a sulfonylurea agent or metformin or both) is indicated. Temporary insulin therapy may be needed during intercurrent illness, surgery or pregnancy. Long-term insulin therapy is recommended in patients with continuing symptoms or hyperglycemia despite treatment with diet modification and orally given hypoglycemic agents. The risk of pancreatitis may be reduced by treating severe hypertriglyceridemia (fasting serum level greater than 10 mmol/L) and atherosclerotic disease through dietary and, if necessary, pharmacologic management of dyslipidemia. Antihypertensive agents are available that have fewer adverse metabolic effects than thiazides and beta-adrenergic receptor blockers. New drugs are being developed that will enhance effective insulin secretion and action and inhibit the progress of complications.

Full text

PDF
1573

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alberti K. G., Gries F. A. Management of non-insulin-dependent diabetes mellitus in Europe: a concensus view. Diabet Med. 1988 Apr;5(3):275–281. doi: 10.1111/j.1464-5491.1988.tb00984.x. [DOI] [PubMed] [Google Scholar]
  2. Bailey C. J. Metformin revisited: its actions and indications for use. Diabet Med. 1988 May-Jun;5(4):315–320. doi: 10.1111/j.1464-5491.1988.tb00996.x. [DOI] [PubMed] [Google Scholar]
  3. Balant L. Clinical pharmacokinetics of sulphonylurea hypoglycaemic drugs. Clin Pharmacokinet. 1981 May-Jun;6(3):215–241. doi: 10.2165/00003088-198106030-00003. [DOI] [PubMed] [Google Scholar]
  4. Barnett A. H., Eff C., Leslie R. D., Pyke D. A. Diabetes in identical twins. A study of 200 pairs. Diabetologia. 1981 Feb;20(2):87–93. doi: 10.1007/BF00262007. [DOI] [PubMed] [Google Scholar]
  5. Bergenstal R. M., Dupre J., Lawson P. M., Rizza R. A., Rubenstein A. H. Observations on C-peptide and free insulin in the blood during continuous subcutaneous insulin infusion and conventional insulin therapy. Diabetes. 1985 Aug;34 (Suppl 3):31–36. doi: 10.2337/diab.34.3.s31. [DOI] [PubMed] [Google Scholar]
  6. Bogardus C., Ravussin E., Robbins D. C., Wolfe R. R., Horton E. S., Sims E. A. Effects of physical training and diet therapy on carbohydrate metabolism in patients with glucose intolerance and non-insulin-dependent diabetes mellitus. Diabetes. 1984 Apr;33(4):311–318. doi: 10.2337/diab.33.4.311. [DOI] [PubMed] [Google Scholar]
  7. Boulton A. J., Levin S., Comstock J. A multicentre trial of the aldose-reductase inhibitor, tolrestat, in patients with symptomatic diabetic neuropathy. Diabetologia. 1990 Jul;33(7):431–437. doi: 10.1007/BF00404095. [DOI] [PubMed] [Google Scholar]
  8. Brass E. P. Effects of antihypertensive drugs on endocrine function. Drugs. 1984 May;27(5):447–458. doi: 10.2165/00003495-198427050-00004. [DOI] [PubMed] [Google Scholar]
  9. Brogden R. N., Todd P. A., Sorkin E. M. Captopril. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure. Drugs. 1988 Nov;36(5):540–600. doi: 10.2165/00003495-198836050-00003. [DOI] [PubMed] [Google Scholar]
  10. Campbell I. W. Metformin and the sulphonylureas: the comparative risk. Horm Metab Res Suppl. 1985;15:105–111. [PubMed] [Google Scholar]
  11. Chockalingam A., Abbott D., Bass M., Battista R., Cameron R., de Champlain J., Evans C. E., Laidlaw J., Lee B. L., Leiter L. Recommendations of the Canadian Consensus Conference on Non-Pharmacological Approaches to the Management of High Blood Pressure, Mar. 21-23, 1989, Halifax, Nova Scotia. CMAJ. 1990 Jun 15;142(12):1397–1409. [PMC free article] [PubMed] [Google Scholar]
  12. Clark A. J., Adeniyi-Jones R. O., Knight G., Leiper J. M., Wiles P. G., Jones R. H., Keen H., MacCuish A. C., Ward J. D., Watkins P. J. Biosynthetic human insulin in the treatment of diabetes. A double-blind crossover trial in established diabetic patients. Lancet. 1982 Aug 14;2(8294):354–357. doi: 10.1016/s0140-6736(82)90548-7. [DOI] [PubMed] [Google Scholar]
  13. Colwell J. A., Bingham S. F., Abraira C., Anderson J. W., Comstock J. P., Kwaan H. C., Nuttall F. Veterans Administration Cooperative Study on antiplatelet agents in diabetic patients after amputation for gangrene: II. Effects of aspirin and dipyridamole on atherosclerotic vascular disease rates. Diabetes Care. 1986 Mar-Apr;9(2):140–148. doi: 10.2337/diacare.9.2.140. [DOI] [PubMed] [Google Scholar]
  14. DeFronzo R. A. Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes. 1988 Jun;37(6):667–687. doi: 10.2337/diab.37.6.667. [DOI] [PubMed] [Google Scholar]
  15. Dunn F. L. Treatment of lipid disorders in diabetes mellitus. Med Clin North Am. 1988 Nov;72(6):1379–1398. doi: 10.1016/s0025-7125(16)30713-1. [DOI] [PubMed] [Google Scholar]
  16. Garg A., Grundy S. M. Management of dyslipidemia in NIDDM. Diabetes Care. 1990 Feb;13(2):153–169. doi: 10.2337/diacare.13.2.153. [DOI] [PubMed] [Google Scholar]
  17. Genuth S. Insulin use in NIDDM. Diabetes Care. 1990 Dec;13(12):1240–1264. doi: 10.2337/diacare.13.12.1240. [DOI] [PubMed] [Google Scholar]
  18. Gerich J. E. Oral hypoglycemic agents. N Engl J Med. 1989 Nov 2;321(18):1231–1245. doi: 10.1056/NEJM198911023211805. [DOI] [PubMed] [Google Scholar]
  19. Glauber H., Wallace P., Griver K., Brechtel G. Adverse metabolic effect of omega-3 fatty acids in non-insulin-dependent diabetes mellitus. Ann Intern Med. 1988 May;108(5):663–668. doi: 10.7326/0003-4819-108-5-663. [DOI] [PubMed] [Google Scholar]
  20. Greene D. A., Sima A. F., Pfeifer M. A., Albers J. W. Diabetic neuropathy. Annu Rev Med. 1990;41:303–317. doi: 10.1146/annurev.me.41.020190.001511. [DOI] [PubMed] [Google Scholar]
  21. Groop L. C., Pelkonen R., Koskimies S., Bottazzo G. F., Doniach D. Secondary failure to treatment with oral antidiabetic agents in non-insulin-dependent diabetes. Diabetes Care. 1986 Mar-Apr;9(2):129–133. doi: 10.2337/diacare.9.2.129. [DOI] [PubMed] [Google Scholar]
  22. Groop L., Widén E., Franssila-Kallunki A., Ekstrand A., Saloranta C., Schalin C., Eriksson J. Different effects of insulin and oral antidiabetic agents on glucose and energy metabolism in type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia. 1989 Aug;32(8):599–605. doi: 10.1007/BF00285334. [DOI] [PubMed] [Google Scholar]
  23. Hamet P., Kalant N., Ross S. A., Wilson T. W., Leenen F. H., Haynes R. B. Recommendations from the Canadian Hypertension Society Consensus Conference on Hypertension and Diabetes. CMAJ. 1988 Dec 1;139(11):1059–1062. [PMC free article] [PubMed] [Google Scholar]
  24. Heller S. R., Macdonald I. A., Tattersall R. B. Counterregulation in type 2 (non-insulin-dependent) diabetes mellitus. Normal endocrine and glycaemic responses, up to ten years after diagnosis. Diabetologia. 1987 Dec;30(12):924–929. doi: 10.1007/BF00295875. [DOI] [PubMed] [Google Scholar]
  25. Henry R. R., Scheaffer L., Olefsky J. M. Glycemic effects of intensive caloric restriction and isocaloric refeeding in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab. 1985 Nov;61(5):917–925. doi: 10.1210/jcem-61-5-917. [DOI] [PubMed] [Google Scholar]
  26. Hermann L. S. Biguanides and sulfonylureas as combination therapy in NIDDM. Diabetes Care. 1990 Aug;13 (Suppl 3):37–41. doi: 10.2337/diacare.13.3.37. [DOI] [PubMed] [Google Scholar]
  27. Hoeg J. M., Gregg R. E., Brewer H. B., Jr An approach to the management of hyperlipoproteinemia. JAMA. 1986 Jan 24;255(4):512–521. [PubMed] [Google Scholar]
  28. Jennings A. M., Wilson R. M., Ward J. D. Symptomatic hypoglycemia in NIDDM patients treated with oral hypoglycemic agents. Diabetes Care. 1989 Mar;12(3):203–208. doi: 10.2337/diacare.12.3.203. [DOI] [PubMed] [Google Scholar]
  29. Johnson J. H., Ogawa A., Chen L., Orci L., Newgard C. B., Alam T., Unger R. H. Underexpression of beta cell high Km glucose transporters in noninsulin-dependent diabetes. Science. 1990 Oct 26;250(4980):546–549. doi: 10.1126/science.2237405. [DOI] [PubMed] [Google Scholar]
  30. Kannel W. B., D'Agostino R. B., Wilson P. W., Belanger A. J., Gagnon D. R. Diabetes, fibrinogen, and risk of cardiovascular disease: the Framingham experience. Am Heart J. 1990 Sep;120(3):672–676. doi: 10.1016/0002-8703(90)90026-t. [DOI] [PubMed] [Google Scholar]
  31. Kennedy D. L., Piper J. M., Baum C. Trends in use of oral hypoglycemic agents 1964-1986. Diabetes Care. 1988 Jul-Aug;11(7):558–562. doi: 10.2337/diacare.11.7.558. [DOI] [PubMed] [Google Scholar]
  32. Kilo C., Miller J. P., Williamson J. R. The Achilles heel of the University Group Diabetes Program. JAMA. 1980 Feb 1;243(5):450–457. [PubMed] [Google Scholar]
  33. Kinoshita J. H., Nishimura C. The involvement of aldose reductase in diabetic complications. Diabetes Metab Rev. 1988 Jun;4(4):323–337. doi: 10.1002/dmr.5610040403. [DOI] [PubMed] [Google Scholar]
  34. Klein R., Klein B. E., Moss S. E., Davis M. D., DeMets D. L. Glycosylated hemoglobin predicts the incidence and progression of diabetic retinopathy. JAMA. 1988 Nov 18;260(19):2864–2871. [PubMed] [Google Scholar]
  35. Klip A., Leiter L. A. Cellular mechanism of action of metformin. Diabetes Care. 1990 Jun;13(6):696–704. doi: 10.2337/diacare.13.6.696. [DOI] [PubMed] [Google Scholar]
  36. Lardinois C. K., Greenfield M. S., Schwartz H. C., Vreman H. J., Reaven G. M. Acarbose treatment of non-insulin-dependent diabetes mellitus. Arch Intern Med. 1984 Feb;144(2):345–347. [PubMed] [Google Scholar]
  37. Larochelle P., Bass M. J., Birkett N. J., De Champlain J., Myers M. G. Recommendations from the Consensus Conference on Hypertension in the Elderly. CMAJ. 1986 Oct 1;135(7):741–745. [PMC free article] [PubMed] [Google Scholar]
  38. Lundholm K., Holm G., Scherstén T. Insulin resistance in patients with cancer. Cancer Res. 1978 Dec;38(12):4665–4670. [PubMed] [Google Scholar]
  39. McCallum R. W., Prakash C., Campoli-Richards D. M., Goa K. L. Cisapride. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use as a prokinetic agent in gastrointestinal motility disorders. Drugs. 1988 Dec;36(6):652–681. doi: 10.2165/00003495-198836060-00002. [DOI] [PubMed] [Google Scholar]
  40. McInnes G. T., Brodie M. J. Drug interactions that matter. A critical reappraisal. Drugs. 1988 Jul;36(1):83–110. doi: 10.2165/00003495-198836010-00006. [DOI] [PubMed] [Google Scholar]
  41. Meinert C. L., Knatterud G. L., Prout T. E., Klimt C. R. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes. 1970;19(Suppl):789–830. [PubMed] [Google Scholar]
  42. Melander A., Lebovitz H. E., Faber O. K. Sulfonylureas. Why, which, and how? Diabetes Care. 1990 Aug;13 (Suppl 3):18–25. doi: 10.2337/diacare.13.3.18. [DOI] [PubMed] [Google Scholar]
  43. Miettinen T. A., Huttunen J. K., Naukkarinen V., Strandberg T., Mattila S., Kumlin T., Sarna S. Multifactorial primary prevention of cardiovascular diseases in middle-aged men. Risk factor changes, incidence, and mortality. JAMA. 1985 Oct 18;254(15):2097–2102. [PubMed] [Google Scholar]
  44. Mogensen C. E. Management of diabetic renal involvement and disease. Lancet. 1988 Apr 16;1(8590):867–870. doi: 10.1016/s0140-6736(88)91611-x. [DOI] [PubMed] [Google Scholar]
  45. Myers M. G., Carruthers S. G., Leenen F. H., Haynes R. B. Recommendations from the Canadian Hypertension Society Consensus Conference on the Pharmacologic Treatment of Hypertension. CMAJ. 1989 May 15;140(10):1141–1146. [PMC free article] [PubMed] [Google Scholar]
  46. Nathan D. M., Roussell A., Godine J. E. Glyburide or insulin for metabolic control in non-insulin-dependent diabetes mellitus. A randomized, double-blind study. Ann Intern Med. 1988 Mar;108(3):334–340. doi: 10.7326/0003-4819-108-3-334. [DOI] [PubMed] [Google Scholar]
  47. Ogbonnaya K. I., Arem R. Diabetic diarrhea. Pathophysiology, diagnosis, and management. Arch Intern Med. 1990 Feb;150(2):262–267. doi: 10.1001/archinte.150.2.262. [DOI] [PubMed] [Google Scholar]
  48. Olefsky J. M. The insulin receptor. A multifunctional protein. Diabetes. 1990 Sep;39(9):1009–1016. doi: 10.2337/diab.39.9.1009. [DOI] [PubMed] [Google Scholar]
  49. Parving H. H., Hommel E., Damkjaer Nielsen M., Giese J. Effect of captopril on blood pressure and kidney function in normotensive insulin dependent diabetics with nephropathy. BMJ. 1989 Aug 26;299(6698):533–536. doi: 10.1136/bmj.299.6698.533. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Peacock I., Tattersall R. B. The difficult choice of treatment for poorly controlled maturity onset diabetes: tablets or insulin? Br Med J (Clin Res Ed) 1984 Jun 30;288(6435):1956–1959. doi: 10.1136/bmj.288.6435.1956. [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Pontiroli A. E., Alberetto M., Secchi A., Dossi G., Bosi I., Pozza G. Insulin given intranasally induces hypoglycaemia in normal and diabetic subjects. Br Med J (Clin Res Ed) 1982 Jan 30;284(6312):303–306. doi: 10.1136/bmj.284.6312.303. [DOI] [PMC free article] [PubMed] [Google Scholar]
  52. Porter J. M., Cutler B. S., Lee B. Y., Reich T., Reichle F. A., Scogin J. T., Strandness D. E. Pentoxifylline efficacy in the treatment of intermittent claudication: multicenter controlled double-blind trial with objective assessment of chronic occlusive arterial disease patients. Am Heart J. 1982 Jul;104(1):66–72. doi: 10.1016/0002-8703(82)90642-1. [DOI] [PubMed] [Google Scholar]
  53. Rains S. G., Wilson G. A., Richmond W., Elkeles R. S. The effect of glibenclamide and metformin on serum lipoproteins in type 2 diabetes. Diabet Med. 1988 Oct;5(7):653–658. doi: 10.1111/j.1464-5491.1988.tb01074.x. [DOI] [PubMed] [Google Scholar]
  54. Reaven G. M., Chen Y. D., Golay A., Swislocki A. L., Jaspan J. B. Documentation of hyperglucagonemia throughout the day in nonobese and obese patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab. 1987 Jan;64(1):106–110. doi: 10.1210/jcem-64-1-106. [DOI] [PubMed] [Google Scholar]
  55. Rossetti L., Giaccari A., DeFronzo R. A. Glucose toxicity. Diabetes Care. 1990 Jun;13(6):610–630. doi: 10.2337/diacare.13.6.610. [DOI] [PubMed] [Google Scholar]
  56. Ryan N. T., George B. C., Egdahl D. H., Egdahl R. H. Chronic tissue insulin resistance following hemorrhagic shock. Ann Surg. 1974 Oct;180(4):402–407. doi: 10.1097/00000658-197410000-00004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  57. Rönnemaa T., Marniemi J., Puukka P., Kuusi T. Effects of long-term physical exercise on serum lipids, lipoproteins and lipid metabolizing enzymes in type 2 (non-insulin-dependent) diabetic patients. Diabetes Res. 1988 Feb;7(2):79–84. [PubMed] [Google Scholar]
  58. SHIPP J. C., CUNNINGHAM R. W., RUSSELL R. O., MARBLE A. INSULIN RESISTANCE: CLINICAL FEATURES, NATURAL COURSE AND EFFECTS OF ADRENAL STEROID TREATMENT. Medicine (Baltimore) 1965 Mar;44:165–186. [PubMed] [Google Scholar]
  59. Scarlett J. A., Gray R. S., Griffin J., Olefsky J. M., Kolterman O. G. Insulin treatment reverses the insulin resistance of type II diabetes mellitus. Diabetes Care. 1982 Jul-Aug;5(4):353–363. doi: 10.2337/diacare.5.4.353. [DOI] [PubMed] [Google Scholar]
  60. Selam J. L., Charles M. A. Devices for insulin administration. Diabetes Care. 1990 Sep;13(9):955–979. doi: 10.2337/diacare.13.9.955. [DOI] [PubMed] [Google Scholar]
  61. Seltzer H. S. Drug-induced hypoglycemia. A review of 1418 cases. Endocrinol Metab Clin North Am. 1989 Mar;18(1):163–183. [PubMed] [Google Scholar]
  62. Shumak S. L. Insulin treatment, NIDDM and atherosclerosis. CMAJ. 1991 Jul 15;145(2):134–134. [PMC free article] [PubMed] [Google Scholar]
  63. Simonson D. C. Effects of glyburide on in vivo insulin-mediated glucose disposal. Am J Med. 1990 Aug 20;89(2A):44S–53S. doi: 10.1016/0002-9343(90)90335-b. [DOI] [PubMed] [Google Scholar]
  64. Siperstein M. D. Diabetic microangiopathy, genetics, environment, and treatment. Am J Med. 1988 Nov 28;85(5A):119–130. doi: 10.1016/0002-9343(88)90404-4. [DOI] [PubMed] [Google Scholar]
  65. Sonnenberg G. E., Berger M. Human insulin: much ado about one amino acid? Diabetologia. 1983 Dec;25(6):457–459. doi: 10.1007/BF00284450. [DOI] [PubMed] [Google Scholar]
  66. Souney P. F., Cyr D. A., Chang J. T., Kaul A. F. Sugar content of selected pharmaceuticals. Diabetes Care. 1983 May-Jun;6(3):231–240. doi: 10.2337/diacare.6.3.231. [DOI] [PubMed] [Google Scholar]
  67. Stern M. P., Patterson J. K., Haffner S. M., Hazuda H. P., Mitchell B. D. Lack of awareness and treatment of hyperlipidemia in type II diabetes in a community survey. JAMA. 1989 Jul 21;262(3):360–364. [PubMed] [Google Scholar]
  68. Temple R. C., Carrington C. A., Luzio S. D., Owens D. R., Schneider A. E., Sobey W. J., Hales C. N. Insulin deficiency in non-insulin-dependent diabetes. Lancet. 1989 Feb 11;1(8633):293–295. doi: 10.1016/s0140-6736(89)91306-8. [DOI] [PubMed] [Google Scholar]
  69. Teuscher A., Egger M., Herman J. B. Diabetes and hypertension. Blood pressure in clinical diabetic patients and a control population. Arch Intern Med. 1989 Sep;149(9):1942–1945. doi: 10.1001/archinte.149.9.1942. [DOI] [PubMed] [Google Scholar]
  70. Vigneri R., Goldfine I. D. Role of metformin in treatment of diabetes mellitus. Diabetes Care. 1987 Jan-Feb;10(1):118–122. doi: 10.2337/diacare.10.1.118. [DOI] [PubMed] [Google Scholar]
  71. Waldhäusl W. K. The physiological basis of insulin treatment--clinical aspects. Diabetologia. 1986 Dec;29(12):837–849. doi: 10.1007/BF00870138. [DOI] [PubMed] [Google Scholar]
  72. Walsh C. H., Soler N. G., James H., Fitzgerald M. G., Malins J. M. Studies on whole-body potassium in non-ketoacidotic diabetics before and after treatment. Br Med J. 1974 Dec 28;4(5947):738–740. doi: 10.1136/bmj.4.5947.738. [DOI] [PMC free article] [PubMed] [Google Scholar]
  73. Warram J. H., Martin B. C., Krolewski A. S., Soeldner J. S., Kahn C. R. Slow glucose removal rate and hyperinsulinemia precede the development of type II diabetes in the offspring of diabetic parents. Ann Intern Med. 1990 Dec 15;113(12):909–915. doi: 10.7326/0003-4819-113-12-909. [DOI] [PubMed] [Google Scholar]
  74. Watkins J. D., Williams T. F., Martin D. A., Hogan M. D., Anderson E. A study of diabetic patients at home. Am J Public Health Nations Health. 1967 Mar;57(3):452–459. doi: 10.2105/ajph.57.3.452. [DOI] [PMC free article] [PubMed] [Google Scholar]
  75. Welle S., Nair K. S., Lockwood D. Effect of a sulfonylurea and insulin on energy expenditure in type II diabetes mellitus. J Clin Endocrinol Metab. 1988 Mar;66(3):593–597. doi: 10.1210/jcem-66-3-593. [DOI] [PubMed] [Google Scholar]
  76. West K. M. Diet therapy of diabetes: an analysis of failure. Ann Intern Med. 1973 Sep;79(3):425–434. doi: 10.7326/0003-4819-79-3-425. [DOI] [PubMed] [Google Scholar]
  77. Westphal S. A., Goetz F. C. Current approaches to continuous insulin replacement for insulin-dependent diabetes: pancreas transplantation and pumps. Adv Intern Med. 1990;35:107–137. [PubMed] [Google Scholar]
  78. Wing R. R., Epstein L. H., Nowalk M. P., Scott N., Koeske R., Hagg S. Does self-monitoring of blood glucose levels improve dietary compliance for obese patients with type II diabetes? Am J Med. 1986 Nov;81(5):830–836. doi: 10.1016/0002-9343(86)90354-2. [DOI] [PubMed] [Google Scholar]
  79. Wing R. R., Epstein L. H., Paternostro-Bayles M., Kriska A., Nowalk M. P., Gooding W. Exercise in a behavioural weight control programme for obese patients with Type 2 (non-insulin-dependent) diabetes. Diabetologia. 1988 Dec;31(12):902–909. doi: 10.1007/BF00265375. [DOI] [PubMed] [Google Scholar]
  80. Zimmerman B. R., Service F. J. Management of noninsulin-dependent diabetes mellitus. Med Clin North Am. 1988 Nov;72(6):1355–1364. doi: 10.1016/s0025-7125(16)30711-8. [DOI] [PubMed] [Google Scholar]

Articles from CMAJ: Canadian Medical Association Journal are provided here courtesy of Canadian Medical Association

RESOURCES